Lonza Group AG

Lonza Group AG is a global leader in contract development and manufacturing services, primarily serving the pharmaceutical, biotechnology, and nutrition sectors. Established in 1897 and headquartered in Basel, Switzerland, the company leverages over a century of expertise to deliver integrated solutions that span the entire lifecycle of therapeutic development, from early-stage research to large-scale commercial production. Lonza's operations are structured around three synergistic platforms: integrated biologics, advanced synthesis, and specialized modalities, which encompass services like mammalian and microbial manufacturing, cell and gene therapy, and the production of highly potent active pharmaceutical ingredients (APIs) and bioconjugates. With a workforce of approximately 18,000 employees and sites across more than 30 countries, Lonza collaborates with a diverse client base—from emerging biotech firms to major global pharmaceutical companies—helping to advance and manufacture innovative therapies and treatments. Renowned as a pioneer in the contract development and manufacturing organization (CDMO) industry, Lonza continues to play a critical role in enabling scientific advancements and ensuring the reliable supply of vital medicines worldwide.